Curaleaf Holdings (TSX:CURA) is back in the spotlight after opening a new Curaleaf Riverview dispensary in Florida. This expansion increases its footprint to 77 locations in the state and 178 across the United States.
Momentum in Curaleaf Holdings has been picking up, with a 5.7% 1-day share price return and a 30.8% year to date share price return pushing the stock to CA$14.05, while the 43.2% 1-year total shareholder return contrasts with weaker 3 and 5 year total shareholder returns, where longer term holders are still sitting on sizable declines.
Spot 8 healthcare AI stocks that, like Curaleaf Holdings, are trying to capture fast growing niches where regulation, technology and patient demand are all reshaping the opportunity set.The business keeps pushing into new markets and revenue grew in the latest year. However, Curaleaf Holdings still reports losses and longer term shareholders are underwater. Is the recent share price jump a fair deal or a stretch?
Most Popular Narrative: 24% Undervalued
Curaleaf Holdings closed at CA$14.05, while the most followed narrative pegs fair value at CA$18.54 using a 6.62% discount rate. That gap hinges on the idea that international expansion and efficiency gains could materially reshape the earnings profile over time.
Ongoing vertical integration and supply chain optimization, including leveraging cultivation facilities in Portugal and bringing beverage fulfillment in-house for the hemp business, are expected to reduce operating costs and enhance margins over time, directly supporting stronger EBITDA and potential margin expansion.
See why 17 investors see Curaleaf Holdings as 24% undervalued.
The same narrative framework assumes Curaleaf Holdings can eventually reach an 11.27% profit margin, with revenue growth of about 9.6% and a future P/E of 23.96x supporting that CA$18.54 figure. Those building their own models can compare that path against current realities such as a CA$1.3b top line, a reported loss of $41.2 million, analyst expectations that the business remains loss making for at least three years, and the fact that earnings are forecast to decline sharply in that window.
Result: Fair Value of CA$18.54 (UNDERVALUED)
Still, the Curaleaf Holdings story hinges on forecasts that could be knocked off course by ongoing losses and any regulatory setbacks in key medical markets, such as Germany or Turkey.
Find out about the key risks to this Curaleaf Holdings narrative.
Next Steps
Curaleaf Holdings clearly divides opinion, with some investors focusing on the losses and others on the expansion and valuation gap. Consider reviewing the figures yourself, then see the 4 key rewards and 3 important warning signs
Looking for more investment ideas beyond Curaleaf Holdings?
If Curaleaf Holdings has your attention, use that momentum to refresh your broader watchlist with a few focused themes that can sharpen your next move.
- Target potential mispricings by scanning for companies that combine quality fundamentals with appealing valuations through the 3 high quality undervalued stocks.
- Strengthen your defense by reviewing the 1 resilient stocks with low risk scores that aim to keep drawdowns in check while you pursue upside elsewhere.
- Get ahead of the crowd by searching the 9 high quality undiscovered gems that the wider market may not be paying attention to yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com